Prognosis at 6 months for coronary and cerebrovascular patients: Impact of antiplatelet agents and statins: Results from the prevenir III study

Cardiovascular Drugs and Therapy

Volumn 20, Issue 1, 2006, Pages 55-61

  Ferrières, Jean ^a,b,d   Cambou, Jean Pierre ^b   Cantet, Christelle ^a   Guize, Louis ^c  

^a CHU RANGUEIL   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d Service de Cardiologie B   (France)

Author keywords

All cause mortality; Antiplatelet agents; Prognosis; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; PRIVATE PRACTICE; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 33646445741     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-6561-2     Document Type: Article

References (27)

1. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901-906.
2. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000;31:2080-2086.
3. Brass LM, Hartigan PM, Page WF, et al. Importance of cerebrovascular disease in studies of myocardial infarction. Stroke 1996;27:1173-1176.
4. Mazoyer E, Drouet L, Soria C, et al. Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude. Thromb Res 1999;95:163-176.
5. Wolfe CD, Giroud M, Kolominsky-Rabas P, et al. Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke 2000;31:2074-2079.
6. Cortellaro M, Boschetti C, Cofrancesco E, et al. and the PLAT Study Group. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992;12:1063-1070.
7. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688-700.
8. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109:1101-1107.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
10. de Backer G, Ambrosioni E, Borch-Johnsen K, et al. European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the European societies and other societies on cardiovascular disease prevention in the clinical practice. Neurologia 2004;19:440-450.
11. Chaturvedi S. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): Is it really practical? Natl Med J India 2004;17:227.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
14. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
15. Gottlieb S, McCarter R, Vogel R. Effect of beta-blockade on mortality among high risk patients after myocardial infarction. N Engl J Med 1998;338:489-497.
16. Gheorghiade M, Goldstein S. Blockers in the post-myocardial infarction patient. Circulation 2002;106:394-398.
17. Antithrombotic Trialists' Collaboration. Prevention of death, myocardial infarction, and stroke by antiplatelet therapy in high-risk patients. BMJ 2002;324:71-86.
18. CAPRIE Steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
19. CURE Steering Commitee. Effects of clopidrogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
20. Pitt B. Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclerosis. Eur Heart J 1995;16:49-54.
21. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
22. European trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
23. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
24. Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: Randomised placebo controlled trial. Lancet 2002;360:7-22.
25. Shepherd J, Blaw GJ, Murphy MB, et al. Pravastatine in elderly individuals at risk of vascular disease (PROSPER: A randomised controled trial). Lancet 2002;360:1623-1630.
26. Hennekens CH, Sacks FM, Tonkin A, et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Andomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med 2004;164:40-44.
27. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischemic heart disease: Nested case-control analysis. BMJ 2005;330:1059-1063.